FIELD: chemistry.
SUBSTANCE: invention relates to a novel tricyclic derivative of chemical formula 1 
or pharmaceutically acceptable salts thereof: formula 1, where Y1, Y2 and Y3 independently denote H, C1-C10 alkyl with a straight or branched chain, hydroxy, C1-C10 alkoxy, -CCOR1, -NR2R3 or -A-B; A denotes -O-, -CH2-, -CH(CH3)-, -CH-N- or -CONH-; B denotes -(CH2)n1-Z, -(CH2)n2-NR2R3 or -(CH2)n3-OR1; Z denotes C5-C20 aryl, unsubstituted or substituted with R5 and selectively R6, C3-C10 cycloalkyl, unsubstituted or substituted with R5 and selectively R6, C1-C20 heterocyclic compound, unsubstituted or substituted with R5 and selectively R6; R1 denotes H or C1-C10 alkyl with a straight or branched chain; R2 and R3 independently denote H, C1-C10 alkyl with a straight or branched chain or -(CH2)n4R7; R5 denotes H, C1-C10 alkyl with a straight or branched chain, C5-C20 aryl or C1-C20 heterocyclic compound; R6 denotes H or C1-C10 alkyl with a straight or branched chain; R7 denotes -NR8R9, -COOR1, -OR1, -CF3, -CN, halogen or Z; R8 and R9 independently denote H or C1-C10 alkyl with a straight or branched chain; n1-n4 respectively denote an integer from 0 to 15; Y denotes H or C1-C10 alkyl with a straight or branched chain. The invention also relates to methods of producing a compound of formula 1, compositions containing the described compound and with effective inhibiting activity on poly(ADP-ribose)polymerase (PARP).
EFFECT: obtaining and describing novel compounds which can be suitable for preventing or treating diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis and cancer.
23 cl, 123 ex, 7 tbl, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL CRYSTALLINE ACID-ADDITION SALTS OF TRICYCLIC DERIVATIVE OR THEIR HYDRATES AND METHOD FOR THEREOF OBTAINING | 2013 |
|
RU2572820C1 |
| TRICYCLIC DERIVATIVES OR THEIR PHARMACEUTICAL SALTS, METHOD OF OBTAINING THEM AND THEIR PHARMACEUTICAL COMPOUNDS | 2004 |
|
RU2326864C2 |
| TRICYCLIC DERIVATIVE COMPOUND, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH A COMPOUND | 2016 |
|
RU2715413C2 |
| NOVEL COMPOUNDS, ISOMERS THEREOF OR PHARMACUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONISTS AND PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUNDS | 2007 |
|
RU2448108C2 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2711502C2 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2014 |
|
RU2681849C2 |
| IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHODS FOR PRODUCTION THEREOF AND USE THEREOF | 2017 |
|
RU2725147C1 |
| HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 2016 |
|
RU2710743C2 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2734390C2 |
| ISOQUINOLINONE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH POLY(ADP-ribose)POLYMERASE-1, CONTAINING THEM AS ACTIVE INGREDIENT | 2020 |
|
RU2815480C1 |
